KOSDAQBiotech & Pharma0009K0

Aimed Bio

₩15,960▼ 0.44%2026-11-18 close
Market Cap
₩1T
Turnover
₩2.7B
Volume
160K
Shares out.
65.1M
PER
30.8×
PBR
5.3×
EPS
₩520
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Licensing income turned the books black; clinical execution is next

Aimed Bio turned profitable in 2025 on licensing income, but a loss in the third quarter of 2026 shows that quarterly results remain volatile. Clinical progress and milestone receipts are the next checkpoints.

  1. 1

    Revenue reached KRW 47.3 billion in 2025, up 302.0% from the prior year, and operating profit of KRW 20.8 billion marked a turn to profit. Press coverage of the filing put licensing income at 99% of revenue.

  2. 2

    Third-quarter 2026 revenue was KRW 1.27 billion and the operating loss was KRW 6.71 billion, returning the quarter to a loss.

  3. 3

    ODS025 (BI 4060107) received FDA Phase 1 clearance in June 2026 alongside a milestone claim, and the Phase 1 start with Boehringer Ingelheim was announced in October 2026.

  4. 4

    The debt ratio stood at 3.3% at end-2025, with total liabilities of KRW 6.4 billion. Conversion of preferred shares into common stock contributed heavily to the improvement.

  5. 5

    A lock-up release of 11,799,426 shares is scheduled for December 4, 2026, leaving a supply overhang.

02

Business structure

Aimed Bio is a biotech developing antibody-drug conjugate (ADC) drugs, spun off from Samsung Medical Center in 2018. The company highlights its patient-derived cell (PDC) and patient-derived xenograft (PDX) platform as the basis for finding oncology targets and selecting candidates.

Its main pipeline has three programs. AMB302, an FGFR3-directed ADC, was licensed to a U.S. biotech partner and is being developed for bladder cancer, head and neck cancer and glioblastoma. AMB303, a ROR1-directed ADC, is being co-developed with SK Plasma, with the company targeting clinical entry within this year.

ODS025 (BI 4060107), licensed to Boehringer Ingelheim, received FDA clearance for a Phase 1 trial in June 2026. Revenue is concentrated in licensing. Licensing income was KRW 46.8 billion of the KRW 47.3 billion 2025 revenue, or 99%, and licensing income was 99.2% of revenue in the first half of 2026.

Deals combine upfront payments, R&D payments and stage-based milestones, and press coverage notes that the timing and size of payments vary by contract. R&D and SG&A expenses together reached KRW 26.5 billion in 2025, roughly double the prior year.

The company competes with domestic and overseas ADC developers, and securing licensing deals with global pharmaceutical companies is the central variable for the business.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4₩38B₩25.5B67.2%
2026Q1₩8.5B-₩4B−46.6%
2026Q2₩20.2B₩8.5B42.2%
2026Q3₩1.3B-₩6.7B−526.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩11.8B-₩400M-₩3.3B−3.5%−98.3%1299.8%
2025₩47.3B₩20.8B₩5B43.9%2.6%3.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue was KRW 47.3 billion in 2025, up 302.0% from KRW 11.8 billion in 2024. Operating profit swung from an operating loss of KRW 408 million in 2024 to operating profit of KRW 20.8 billion in 2025, and the operating margin moved from -3.5% to 43.9%.

Profit attributable to owners of the parent went from a net loss of KRW 3.3 billion in 2024 to a net profit of KRW 5.02 billion in 2025. Net profit including non-controlling interests went from a net loss of KRW 3.31 billion to a net profit of KRW 5.02 billion over the same period.

The gap between operating profit and net profit reflects a non-cash valuation loss recognized when convertible and redeemable preferred shares converted into common stock, as the company explained when it released preliminary results. Operating cash flow went from -KRW 4.87 billion in 2024 to KRW 17.9 billion in 2025.

At end-2025, total equity was KRW 192.6 billion, all of it attributable to owners of the parent, and total liabilities were KRW 6.4 billion. The debt ratio fell from 1,299.8% in 2024 to 3.3% in 2025.

On a quarterly basis, fourth-quarter 2025 revenue was KRW 38 billion, operating profit was KRW 25.5 billion and profit attributable to owners was KRW 34.9 billion. No quarterly figures are available for the third quarter of 2025.

In the first quarter of 2026, revenue was KRW 8.5 billion, the operating loss was KRW 3.96 billion and the net loss attributable to owners was KRW 2.01 billion. In the second quarter, revenue was KRW 20.2 billion, operating profit was KRW 8.52 billion and profit attributable to owners was KRW 10.9 billion.

In the third quarter, revenue fell to KRW 1.27 billion, with an operating loss of KRW 6.71 billion and a net loss attributable to owners of KRW 9.53 billion. Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, profit attributable to owners totaled KRW 34.3 billion.

Quarterly revenue moves with the timing of revenue recognition under licensing contracts, and because R&D spending is heavy, quarters with low revenue show operating losses.

05

Industry analysis

The ADC market pairs antibodies with cytotoxic payloads to target cancer cells, and carrying a candidate from Phase 1 through late-stage trials costs several hundred billion won.

Press reports say large pharmaceutical companies have become cautious about licensing before early clinical data are in hand, which has led more biotechs to fund development themselves through certain stages.

In this setting, Aimed Bio has secured upfront payments and milestones through licensing deals first, with further fees tied to clinical entry, and the company is cited as differentiated on that structure.

On the other hand, platform value is diluting quickly across the ADC market, and some observers argue that how fast a company moves competitive candidates into the clinic determines its enterprise value.

Among listed peers, the company is co-developing an ADC toolbox with Samsung Biologics, which Mirae Asset Securities analyst Seo Mi-hwa said in June 2026 could be offered to CDMO customers.

The company is also widening its pipeline into the central nervous system and expanding joint research with AI firms, and it made strategic investments in two AI companies in the first half of 2026.

06

Outlook

In a fair disclosure filing in March 2026, the company guided to 2026 consolidated revenue of KRW 56.3 billion and operating profit of KRW 18.1 billion.

The figures were adjusted from the IPO prospectus outlook (revenue of KRW 27.6 billion and operating profit of KRW 9.9 billion) because of clearer accounting treatment for some contracts, a change in the exchange-rate assumption from KRW 1,340 to KRW 1,450 per dollar, and the inclusion of additional business opportunities.

In July 2026 investor-relations materials, the company presented expected year-end 2026 financials of annual revenue above KRW 50 billion and financial assets of about KRW 200 billion, according to press reports. First-half 2026 revenue was KRW 28.7 billion and operating profit was KRW 4.6 billion.

Third-quarter revenue of KRW 1.27 billion means the first three quarters together account for a bit more than half of the March guidance, so fourth-quarter licensing recognition is the key variable for reaching it.

On the pipeline side, ODS025 received FDA Phase 1 clearance in June 2026 with an accompanying milestone claim of more than 10% of 2025 consolidated revenue, although the amount is confidential under contract terms.

The company listed an interim dose-escalation cohort readout for AMB302 as a second-half 2026 milestone and said it is pursuing an IND submission for AMB303 within the year.

The company also presented 2030 targets of a KRW 20 trillion market capitalization, more than 15 clinical pipeline programs and cumulative licensing deals above KRW 12 trillion, which are management goals rather than forecasts. In August 2026 the company also announced a share issuance tied to exercised subscription rights.

07

Valuation

PER
30.8×
PBR
5.3×
ROE
23.8%
EPS
₩520
BPS
₩3,019
Dividend per share
₩0

Valuation can be read on two bases, earnings and net assets. Total equity at end-2025 was KRW 192.6 billion, all attributable to owners of the parent, and the market capitalization sits well above that book value, so the price-to-book ratio reflects a large premium over net assets.

On an earnings basis, profit attributable to owners over the last four quarters totaled KRW 34.3 billion, but it swung sharply from quarter to quarter, so the same market value can look very different depending on the period used. 2025 was the first profitable year, and much of the profit came from licensing fees that are not recurring in nature, which makes earnings multiples difficult to compare with past trends.

The dividend yield is effectively zero, so the equity case rests mainly on pipeline value and milestone receipts rather than on shareholder payouts.

Press coverage identified early clinical data from AMB302, the global Phase 1 progress of ODS025, and preclinical data for AMB303 and AMB305 as the main variables for enterprise value in the second half of 2026. Lock-up releases and share issuance were cited as factors that could weigh on the stock.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Turn to profit on licensing

Operating profit of KRW 20.8 billion in 2025 marked a turn from an operating loss, and operating cash flow moved to KRW 17.9 billion. The operating margin reached 43.9%. Press reports on the semi-annual report said first-half 2026 revenue of KRW 28.7 billion more than tripled year on year. Licensing deals sit at the center of these results.

Financial capacity

The debt ratio was 3.3% at end-2025, with total equity of KRW 192.6 billion. Press reports said the company raised about KRW 121.9 billion through third-party and public offerings in 2025. Cash and short-term financial instruments were reported at around KRW 170.8 billion. The company cites this capacity as a base for expanding in-house clinical development.

Clinical entry and milestone structure

ODS025 received FDA Phase 1 clearance in June 2026, and a Phase 1 start with Boehringer Ingelheim was announced in October 2026. The company said the milestone claim exceeds 10% of 2025 revenue.

An interim AMB302 Phase 1 readout is listed for the second half of 2026, and clinical data from it could make further milestone structures more visible.

09

Bear factors

Revenue depends on licensing fees

Licensing income was 99% of 2025 revenue, and the same structure held at 99.2% in the first half of 2026. Analysts note that milestone timing and size vary by contract, which makes earnings more volatile than at typical pharmaceutical companies.

The company has also disclosed that licensing agreements could end if clinical, approval or commercialization steps do not proceed as planned.

Recurring quarterly operating losses

After a first-quarter 2026 operating loss of KRW 3.96 billion, the third quarter also posted an operating loss of KRW 6.71 billion. Third-quarter revenue fell to KRW 1.27 billion. R&D and SG&A expenses together reached KRW 26.5 billion in 2025, roughly double the prior year. In quarters with low licensing revenue, fixed R&D spending translates into losses.

Supply overhang and dilution

A lock-up on 10,595,547 shares lapsed on February 4, 2026, and a further 11,799,426 shares are scheduled to be released on December 4, 2026. A share issuance tied to exercised subscription rights was announced in August 2026. Founder and board chairman Nam Do-hyun is reported as the largest shareholder with a 34.55% stake.

10

Risk factors

Clinical development risk

ADC development costs several hundred billion won from Phase 1 through late-stage trials. If clinical data fall short, later licensing and milestone receipts could be delayed or stop. The ODS025 Phase 1 is planned for about 90 participants over roughly three years, with dose-limiting toxicity as the primary measure.

Concentration in licensing income

Licensing income makes up 99% of revenue, so the timing of specific contracts drives results. When milestone claims cluster, quarterly revenue jumps, and without receipts revenue can fall sharply. Third-quarter 2026 revenue of KRW 1.27 billion illustrates this volatility.

Liquidity and share supply

The December 4, 2026 lock-up release and share issuance tied to subscription rights could increase the supply of shares. As the company spends on in-house clinical expansion, the pace of cash use is also a point to monitor. The largest shareholder's high stake means changes in free float are worth watching.

11

What to watch next

  1. December 4, 2026

    A release of 11,799,426 shares from lock-up is scheduled. The pace at which the shares reach the market and the resulting supply changes are the points to watch.

  2. Second half of 2026 (by year-end)

    The interim readout from the AMB302 Phase 1 dose-escalation cohort is a second-half 2026 milestone the company listed. Safety and early tumor-response data will form the basis for the follow-on development path.

  3. End of 2026

    The company targets an IND submission for AMB303 within 2026, which will indicate how quickly the follow-on pipeline is entering the clinic.

  4. Fiscal year-end 2026

    The 2026 guidance of KRW 56.3 billion in revenue and KRW 18.1 billion in operating profit will be compared with full-year results. Fourth-quarter licensing recognition will determine the gap.

  5. By end-March 2027

    The company said full-year 2026 results will be reflected in the ninth-term annual report. The operating margin and cash flow confirmed in that report will be the next filed earnings baseline.

12

Overall view

Aimed Bio turned profitable in 2025 with revenue of KRW 47.3 billion and operating profit of KRW 20.8 billion, and operating cash flow turned positive at KRW 17.9 billion.

The debt ratio fell to 3.3% that year, but that change also reflects the effect of preferred shares converting to common stock alongside licensing income.

In 2026, quarterly direction alternated, with an operating loss in the first quarter, a profit in the second and a loss in the third, and profit attributable to owners over the last four quarters totaled KRW 34.3 billion.

Because most revenue comes from licensing contracts, results can shift sharply depending on revenue recognition timing and milestone receipts. Strengths cited include the FDA Phase 1 clearance for ODS025, the financial capacity built on licensing income, and the timing of the AMB302 interim readout.

Weaknesses cited include dependence on licensing fees, quarterly operating losses, and supply pressure from the December 2026 lock-up release and share issuance.

The next checkpoints are how close 2026 year-end results come to the March guidance, and the operating margin and cash flow in the 2026 annual report due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. aimedbio.com
  2. etoday.co.kr
  3. thebionews.net
  4. medicopharma.co.kr
  5. supple.kr
  6. supple.kr
  7. medicopharma.co.kr
  8. newstomato.com
  9. digitaltoday.co.kr
  10. docdocdoc.co.kr
  11. news.nate.com
  12. m.news.nate.com
  13. newspim.com
  14. m.news.nate.com
  15. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis